Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Cystic fibrosis - ETI and type 2 N-of-1 trials : the next step].

Revue medicale de Liege - 1 Oct 2023

Lebecque Patrick, Bauraind Olivia, Thimmesch Matthieu

Abstract excerpt

In evidence-based medicine, N-of-1 trials are increasingly attractive for rare and heterogeneous conditions. A recent French study illustrates this convincingly in the field of cystic fibrosis. A highly effective triple therapy (ETI) is currently available in Europe, which will eventually help the 85 % of Belgian patients carrying at least one copy of the F508del mutation. Most other 2.000 or so putative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator
Share to Europe

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Reproducibility of Results

Source

Identifiers

PMID: 37830320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Cystic fibrosis - ETI and type 2 N-of-1 trials : the next step].PMID 37830320Read ↗

Organoid Guided N-of-1 (ORIGIN-1) Clinical Trial: A phase 4 study to investigate if people with cystic fibrosis with rare non-F508del CFTR mutations with an in-vitro response to Elexacaftor/ Tezacaftor/ Ivacaftor have a clinically meaningful response to Elexacaftor/ Tezacaftor/ Ivacaftor versus placebo.Semantic proximity Read ↗

[Therapeutics in cystic fibrosis: Clinical revolution and new challenges].Semantic proximity Read ↗

[Cystic fibrosis prognosis in Europa : chronicle of an announced dilemma].Semantic proximity Read ↗

[Therapeutic advances in cystic fibrosis: from genetics to treatment personalized].Semantic proximity Read ↗

ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations.Semantic proximity Read ↗

[News drugs and evolution towards personalized treatment for cystic fibrosis].Semantic proximity Read ↗

Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries.Semantic proximity Read ↗

CFTR Complex Alleles in Individuals with Cystic Fibrosis Showing Limited Response to Elexacaftor/Tezacaftor/Ivacaftor (ETI) Triple Modulator TherapySemantic proximity Read ↗

Treatment burden in patients with at least one class IV or V CFTR mutation.Semantic proximity Read ↗

The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis.Semantic proximity Read ↗

Screening by high-throughput sequencing for pathogenic variants in cystic fibrosis: Benefit of introducing personalized therapies.Semantic proximity Read ↗

Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.